Charles River Laboratories International Inc. (NYSE: CRL) plans to acquire Wil Research, which provides services to biopharmaceutical and industrial chemical companies, for about $585 million in cash.
According to Wilmington, Massachusetts-based Charles River, acquiring the company will help Charles River’s position as an early-stage contract research organization by strengthening its ability to work with more clients globally in the area of drug discovery and development. Wil Research provides safety assessment and contract development and manufacturing services. Charles River provides products and services to clients in the drug research and development business, including pharmaceutical and biotechnology companies. With headquarters in Ashland, Ohio, Wil Research has offices in The Netherlands, France, the U.K. and Japan.